Guardant Health is a precision oncology company founded in 2012, headquartered in Palo Alto, California. The company develops blood-based tests, known as liquid biopsies, to aid in cancer detection, treatment selection, and monitoring. Its work sits at the intersection of oncology, diagnostics, and biopharma, with a stated mission to conquer cancer with data.
The company's portfolio includes several notable products. Shield is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults aged 45 and older. Guardant360 CDx was the first FDA-approved blood test for comprehensive genomic profiling. Guardant Reveal is used for cancer detection and management. These tests are developed and processed in CLIA-certified, CAP-accredited laboratories.
Guardant Health has performed over 500,000 blood tests to date, with more than 12,000 doctors using its tests. The company operates across the Americas, Europe, Asia, the Middle East, and Africa. Its technical domains include liquid biopsy, genomic profiling, precision oncology, and real-world evidence.
